Fatal danaparoid-sodium induced thrombocytopenia and arterial thromboses.
B
B
Tardy
B
B
Tardy-Poncet
A
A
Viallon
M
M
Piot
E
E
Mazet
D000368:Aged; D000925:Anticoagulants / Q000009:adverse effects* / Q000627:therapeutic use*; D001158:Arteries / Q000473:pathology; D002809:Chondroitin Sulfates / Q000009:adverse effects* / Q000627:therapeutic use*; D003871:Dermatan Sulfate / Q000009:adverse effects* / Q000627:therapeutic use*; D004338:Drug Combinations; D017809:Fatal Outcome; D006496:Heparinoids / Q000009:adverse effects / Q000627:therapeutic use; D006497:Heparan Sulfate / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011655:Pulmonary Embolism / Q000188:drug therapy*; D013921:Thrombocytopenia / Q000139:chemically induced*; D013927:Thrombosis / Q000139:chemically induced*
D000925:Anticoagulants; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D004338:Drug Combinations; D006496:Heparinoids; D006497:Heparan Sulfate; C035838:danaparoid